HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Telemedicine in oncology: Virtual solution to a very real problem

Point/Counter

Is home-based remote monitoring ready for prime time in oncology?

Editorial

On killing innocents: Anzac Day revisited

Derek Raghavan, MD, PhD

Advanced Practice

Hazardous drug exposures: Implications for the oncology APP

Christopher R. Friese, PhD, RN, AOCN®, FAAN

Feature

Telemedicine working group aims to address ‘big gaps’ of emergency cancer care

Meeting News

Diet, supplements may affect immunotherapy response among patients with melanoma

Liquid biopsy comparable to tissue biopsy in detecting biomarkers in NSCLC

Savolitinib, osimertinib combination may benefit certain patients with EGFR-mutated lung cancer

Standards evolve for adjuvant therapy of melanoma

Immunotherapy-chemotherapy combination should be first-line treatment for many patients with NSCLC

More immunotherapy regimens ‘desperately needed’ for salvage treatment of advanced NSCLC

Niraparib extends time without symptoms for women with recurrent ovarian cancer

Brachytherapy improves survival in advanced cervical cancer, but racial disparities remain

Meeting News

Dendritic cell-based immunotherapy regimen extends OS in recurrent ovarian cancer

Pregnancy among young women with breast cancer requires tailored support, multidisciplinary approach

Extent of sentinel lymph node biopsy influences lymphedema risk

Pembrolizumab plus axitinib new standard first-line treatment for advanced kidney cancer

Tivozanib shows PFS benefit over sorafenib for advanced kidney cancer

Sacituzumab govitecan response rates 'promising' in metastatic urothelial cancer

In the Journals

Pembrolizumab shows durable survival benefit in advanced non-small cell lung cancer

Allogeneic transplant fails to confer survival benefit for pediatric leukemia subtype

Direct oral anticoagulants do not increase incidence of intracranial hemorrhage

Right to Try Act may undermine palliative care in pediatric oncology

Daunorubicin linked to lower cardiomyopathy risk than doxorubicin in childhood cancer survivors

FDA News

Atezolizumab plus chemotherapy approved for triple-negative breast cancer, small cell lung cancer

FDA advisory committee calls for more data on selinexor for relapsed multiple myeloma

FDA approves Lonsurf for adults with metastatic gastric, gastroesophageal junction adenocarcinoma